CN107108561A
|
|
Heteroaryl compound as IRAK inhibitor and application thereof
|
WO2010101622A1
|
|
Lung cancer treatment
|
US2010145038A1
|
|
RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
|
ZA200907667B
|
|
Antigen-binding proteins targeting S. Aureus ORF0657N
|
WO2010044893A1
|
|
Combination therapy
|
TW201008927A
|
|
Tripyridyl carboxamide orexin receptor antagonists
|
WO2010017056A1
|
|
Orally administered solid formulations containing a hydrophobic drug and tpgs
|
TW201102374A
|
|
Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
|
WO2010005841A1
|
|
Inhibitors of janus kinases
|
WO2009155538A1
|
|
Compositions and methods of depleting amyloid-beta peptides from cerebrospinal fluid to treat alzheimer's disease
|
TW200951133A
|
|
P38 kinase inhibiting agents
|
WO2009152027A1
|
|
5,7-dihydro-6h-pyrrolo[2,3-d]pyrimidin-6-one derivatives for mark inhibition
|
WO2009152025A1
|
|
Imidazole derivatives useful as inhibitors of faah
|
WO2009148887A1
|
|
Inhibitors of akt activity
|
WO2009151800A1
|
|
Soluble epoxide hydrolase inhibitors, compositions containing such compounds and methods of treatment
|
WO2009154870A1
|
|
Hiv integrase inhibitors
|
WO2009131930A1
|
|
Nanoparticle formation via rapid precipitation
|
WO2009131852A1
|
|
Pancreatic beta-cell mass biomarker
|
WO2009129036A1
|
|
Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
|
WO2009108546A1
|
|
Ahcy hydrolase inhibitors for treatment of hyper homocysteinemia
|